Lee Chung-Lin, Chen Pei-Sin, Lu Yu-Ying, Chiang Yu-Ting, Yen Ching-Tzu, Huang Chun-Ying, Cheng Yen-Fu, Lin Hsiang-Yu, Chen Yun-Ru, Niu Dau-Ming
Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan; Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.
Can J Cardiol. 2025 May;41(5):939-951. doi: 10.1016/j.cjca.2025.03.001. Epub 2025 Mar 7.
Fabry disease (FD) is a lysosomal storage disorder impacting multiple organs, including the heart. In this study we investigated whether early-stage globotriaosylceramide (Gb3) accumulation, occurring before the formation of inclusion bodies, could cause significant stress and potentially irreversible damage of the cardiac tissue in patients with FD.
Immunofluorescent staining and Western blotting were performed on fibroblasts from FD IVS4 patients and myocardial biopsies from G3Stg/GLAko mice as well as 3 IVS4 patients (aged 44, 37, and 41 years). Notably, all biopsies showed detectable Gb3 accumulation under immunoflourescence (IF) but lacked the typical pathology of FD (Gb3 inclusion bodies). Staining targeted nuclear factor-kappaB (NF-κB), interleukin-18 (IL-18), phospho-p42/44 mitogen-activated protein kinase (MAPK), and inducible nitric oxide synthase (iNOS) as markers of inflammation and oxidative stress. In addition, α-smooth muscle actin (α-SMA) IF staining was conducted to identify myofibroblasts.
Fibroblasts from FD patients, along with cardiac tissues from both G3Stg/GLAko mice and FD patients, exhibited significant accumulation of inflammatory markers such as NF-κB IL-18, and phospho-p42/44 MAPK, as well as the oxidative stress marker iNOS. Despite the absence of typical FD pathology, the presence of fibrogenesis was confirmed in myocardial biopsies from these patients through strong positive staining of α-SMA.
Significant cellular stress and potential irreversible damage may occur before the onset of typical pathologic changes in the cardiac tissues of FD patients. Our findings raise an intriguing question: Should enzyme replacement therapy be initiated much earlier than currently recommended? To answer this, validation through rigorous randomized controlled trials is needed to draw definitive conclusions.
法布里病(FD)是一种影响包括心脏在内多个器官的溶酶体贮积症。在本研究中,我们调查了在包涵体形成之前发生的早期阶段的 globotriaosylceramide(Gb3)蓄积是否会导致 FD 患者心脏组织出现显著应激以及潜在的不可逆损伤。
对 FD IVS4 患者的成纤维细胞、G3Stg/GLAko 小鼠的心肌活检组织以及 3 例 IVS4 患者(年龄分别为 44 岁、37 岁和 41 岁)的心肌活检组织进行免疫荧光染色和蛋白质印迹分析。值得注意的是,所有活检组织在免疫荧光(IF)下均显示可检测到的 Gb3 蓄积,但缺乏 FD 的典型病理特征(Gb3 包涵体)。染色针对核因子 -κB(NF -κB)、白细胞介素 -18(IL -18)、磷酸化 p42/44 丝裂原活化蛋白激酶(MAPK)和诱导型一氧化氮合酶(iNOS)作为炎症和氧化应激的标志物。此外,进行α -平滑肌肌动蛋白(α -SMA)IF 染色以鉴定肌成纤维细胞。
FD 患者的成纤维细胞以及 G3Stg/GLAko 小鼠和 FD 患者的心脏组织均表现出炎症标志物如 NF -κB、IL -18 和磷酸化 p42/44 MAPK 以及氧化应激标志物 iNOS 的显著蓄积。尽管没有典型的 FD 病理特征,但通过α -SMA 的强阳性染色在这些患者的心肌活检组织中证实了纤维化的存在。
在 FD 患者心脏组织典型病理变化出现之前,可能就会发生显著的细胞应激和潜在的不可逆损伤。我们的研究结果提出了一个有趣的问题:酶替代疗法是否应比目前推荐的时间更早开始?要回答这个问题,需要通过严格的随机对照试验进行验证才能得出明确结论。